Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer

World Journal of Surgical Oncology

Jihui Jia¹  Xiuzhen Fan¹  Yulan Bu¹  Hua Gao²  Yan Zhang¹ 

[1] Department of Nursing, Qilu Hospital and School of Nursing, Shandong University, West Wenhua Road, Ji'nan, Shandong 250012, P.R China;Tianchen Hospital of Zaozhuang Mining Group, Tianchen Town, Zaozhuang City 277500, P.R China

关键词: Neoadjuvant chemotherapy;    Epidemiology;    Adjuvant chemotherapy;    Breast cancer;   

Others  :  821000
DOI  :  10.1186/1477-7819-11-286

 received in 2013-01-14, accepted in 2013-10-18,  发布年份 2013

【 摘 要 】

Background

Adjuvant chemotherapies are recommended for most women after breast cancer surgery, and can greatly affect the patients’ survival. We describe and evaluate possible factors influencing receipt of postoperative adjuvant chemotherapy among breast cancer patients in China.

Methods

A total of 1,431 women diagnosed with breast cancer from 1997 to 2005 were enrolled. We reviewed medical records and abstracted information about these patients. Details on social-demographic factors and clinical-pathological characteristics of participants were collected and analyzed. To meet our objectives, the patient’s age at diagnosis, comorbidities, menstrual status, rural/urban status, tumor size, lymph node status, distant metastasis, tumor stage and hormone receptor status were estimated.

Results

Overall, 936 of these 1,431 patients (65.41%) received adjuvant chemotherapy. Receipt of chemotherapy was significantly associated with age at diagnosis, rural–urban disparities, and lymph node status of patients, though no significant difference was found between the age <50 and age 50 to 64 groups. Moderate association was also observed between hormone receptor status and receipt of adjuvant chemotherapy, though it was still not statistically significant.

Conclusions

Our study suggests that age at diagnosis, rural–urban disparities and lymph node status of breast cancer patients are independent predictors for receipt of adjuvant chemotherapy among married Chinese women. Further investigations are warranted, and related public health education needs to be expanded in China.

【 授权许可】

   
2013 Zhang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jemal A, Bray F, Melissa M, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Bonadonna G, Valagussa P: Dose–response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981, 304:10-15.
• [3]Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB Investigators: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
• [4]Consensus NIH: Statement. Adjuvant Therapy for Breast Cancer 2000, 17:1-35.
• [5]Consensus conference: Adjuvant chemotherapy for breast cancer. JAMA 1985, 254:3461-3463.
• [6]NIH consensus conference: Treatment of early-stage breast cancer. JAMA 1991, 265:391-395.
• [7]Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB, Ward KC: Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 2012, 133:285-296.
• [8]Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS: Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009, 27:2157-2162.
• [9]Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA: Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006, 24:1357-1362.
• [10]China. SstoNBoSo: Fifty years of cities of People’ s Republic of China. Beijing: Xinhua Press; 1999.
• [11]Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006, 24:2750-2756.
• [12]Richardson LC, Tian L, Voti L, Hartzema AG, Reis I, Fleming LE, Mackinnon J: The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Public Health 2006, 96:160-166.
• [13]Glick JH, Gelber RD, Goldhirsch A, Senn HJ: Adjuvant therapy of primary breast cancer. 4th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol 1992, 3:801-807.
• [14]Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001, 19:3817-3827.
• [15]Rao RD, Cobleigh MA: Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 2012, 26:541-547. 550, 552 passim
• [16]Silliman RA, Guadagnoli E, Weitberg AB, Mor V: Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 1989, 44:M46-M50.
• [17]Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS: Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med 2003, 138:90-97.
• [18]Bickell NA, Aufses AH Jr, Chassin MR: The quality of early-stage breast cancer care. Ann Surg 2000, 232:220-224.
• [19]Breen N, Wesley MN, Merrill RM, Johnson K: The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Ethn Dis 1999, 9:111-125.
• [20]Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 2002, 94:490-496.
• [21]Kisker EE, Goldman N: Perils of single life and benefits of marriage. Soc Biol 1987, 34:135-152.
• [22]Kravdal O: The impact of marital status on cancer survival. Soc Sci Med 2001, 52:357-368.
• [23]Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P: Sources of support and the physical and mental well-being of young women with breast cancer. Soc Sci Med 2001, 53:1513-1524.
• [24]Du X, Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001, 19:1455-1461.
• [25]Buist DS, Chubak J, Prout M, Yood MU, Bosco JL, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA: Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. J Clin Oncol 2009, 27:4508-4514.
• [26]Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003, 21:3580-3587.
• [27]Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H, Cancer Leukemia Group B: Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol 2010, 28:3146-3153.